CAY10502|cas:888320-29-4|西域试剂

CAY10502

产品编号：Bellancom-116301| CAS NO：888320-29-4| 分子式：C₃₀H₃₇NO₇| 分子量：523.62

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-116301		￥2600.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

CAY10502

产品介绍

CAY10502 是一种有效的钙依赖性胞质磷脂酶 A2 α (cPLA₂α) 抑制剂，对分离的酶具有 IC₅₀ 为 4.3 nM。CAY10502 可用于视网膜病变和炎症性疾病的研究。

生物活性

CAY10502 is a potent, calcium-dependent cytosolic phospholipase A2 α (cPLA₂α) inhibitor with an IC₅₀ of 4.3 nM for isolated enzyme. CAY10502 can be used in the research of retinopathy and inflammatory diseases.

体外研究

CAY10502 inhibits the release of arachidonic acid mediated by cPLA2R stimulanted with A23187 and TPA in human platelets, with IC₅₀s of 0.57 and 0.0009 μM, respectively.
CAY10502 (5, 20, 50 nM; 12 hours; müller cells) inhibits normoxic- and hypoxia-induced Prostaglandin E₂ (PGE₂) and VEGF production.
CAY10502 (0.1-100 nM; 24 hours) inhibits the VEGF-induced proliferation of rat retinal microvascular endothelial cells (RRMEC).
CAY10502 (10 μM) inhibits arachidonic acid (AA) release from the phospholipid pools, abrogated extremely low-frequency electromagnetic fields (ELF-EMF; 1 h) induced AA increase and the ELF-EMF inhibitory effect of Cav3.2 channels.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:	RRMEC
Concentration:	0.1-100 nM
Incubation Time:	24 hours
Result:	CAY10502 (35, 50 nM) demonstrated significant reductions in VEGF-induced proliferation (64.3% and 84.1%, respectively) compared with cultures treated with VEGF alone.

体内研究
(In Vivo)

CAY10502-injected (2.5, 25, 100 nM; 5 μL) eyes demonstrates a dose-dependent inhibition of retinal neovascularization (NV) in rat oxygen-induced retinopathy (OIR).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	OIR and room air (RA) Sprague-Dawley rat
Dosage:	2.5, 25, 100 nM; 5 μL
Administration:	Intravitreal Injection
Result:	Injection of 100 nM CAY10502 resulted in a 53.1% reduction in NV compared with vehicle treatment.

体内研究

CAY10502-injected (2.5, 25, 100 nM; 5 μL) eyes demonstrates a dose-dependent inhibition of retinal neovascularization (NV) in rat oxygen-induced retinopathy (OIR).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	OIR and room air (RA) Sprague-Dawley rat
Dosage:	2.5, 25, 100 nM; 5 μL
Administration:	Intravitreal Injection
Result:	Injection of 100 nM CAY10502 resulted in a 53.1% reduction in NV compared with vehicle treatment.

体内研究

CAY10502-injected (2.5, 25, 100 nM; 5 μL) eyes demonstrates a dose-dependent inhibition of retinal neovascularization (NV) in rat oxygen-induced retinopathy (OIR).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	OIR and room air (RA) Sprague-Dawley rat
Dosage:	2.5, 25, 100 nM; 5 μL
Administration:	Intravitreal Injection
Result:	Injection of 100 nM CAY10502 resulted in a 53.1% reduction in NV compared with vehicle treatment.